

Clinical Policy: Surgical Excision of Eyelid Lesions

Reference Number: CP.VP.75

Last Review Date: 08/2025

Coding Implications
Revision Log

See Important Reminder at the end of this policy for important regulatory and legal information.

Description

The majority of eyelid lesions are benign, ranging from innocuous cysts and chalazion/hordeolum to nevi and papillomas. Key features that should prompt further investigation include gradual enlargement, central ulceration or induration, irregular borders, eyelid margin destruction or loss of lashes, and telangiectasia. This policy describes the medical necessity requirements for surgical excision of eyelid lesions.

Policy/Criteria

- I. It is the policy of health plans affiliated with Centene Corporation® (Centene) and Envolve Vision, Inc.® (Envolve) that surgical excision and repair of eyelid or conjunctiva due to lesion or cyst or eyelid foreign body removal is **medically necessary** for any of the following indications:
 - **A.** Lesion with one or more of the following characteristics:
 - 1. Bleeding;
 - 2. Persistent or intense itching;
 - 3. Pain;
 - 4. Inflammation;
 - 5. Restricts vision or eyelid function;
 - 6. Misdirects eyelashes or eyelid;
 - 7. Displaces lacrimal puncta or interferes with tear flow;
 - 8. Touches globe;
 - 9. Unknown etiology with potential for malignancy.
 - **B.** Lesions classified as one of the following:
 - 1. Malignant;
 - 2. Benign;
 - 3. Cutaneous papilloma;
 - 4. Cysts;
 - 5. Embedded foreign bodies.
 - C. Periocular warts associated with chronic conjunctivitis.

Background

The majority of eyelid lesions are benign, ranging from innocuous cysts and chalazion/hordeolum to nevi and papillomas. Key features that should prompt further investigation include gradual enlargement, central ulceration or induration, irregular borders, eyelid margin destruction or loss of lashes, and telangiectasia.

Benign tumors, even though benign, often require removal and therefore must be examined carefully and the differential diagnosis of a malignant eyelid tumor considered and the method of removal planned. The lesion is examined with respect to its size, shape, color, level in the eyelid, mobility, tethering and tenderness. The peri-orbital area is examined for additional lesions. If a malignant tumor is suspected, additional evaluation including a full medical examination may be needed and other specialists including an oculoplastic surgeon, dermatologist, oncologist and head and neck surgeon may be consulted in more advanced cases.





The treatment of eyelid lesions depends on the diagnosis which is obtained by biopsy. Benign eyelid lesions are excised in full and ocular reconstruction performed using direct closure, flaps or grafts. Malignant tumors may require adjuvant treatment with either radiotherapy or chemotherapy after excision, depending on the diagnosis. Surgery of eyelid lumps and bumps can frequently be done under local anesthesia.

A chalazion or meibomian cyst is caused by inflammation of a blocked meibomian gland. Chalazia differ from styes (hordeola) in that they are subacute and usually painless nodules. They may become acutely inflamed, but unlike a stye, chalazia usually sit inside the lid rather than on the lid margin. The surgical excision procedure of a chalazion varies depending on the chalazion's texture. Chalazion excision is usually an ambulant procedure with local anesthesia.

Coding Implications

This clinical policy references Current Procedural Terminology (CPT®). CPT® is a registered trademark of the American Medical Association. All CPT codes and descriptions are copyrighted 2025, American Medical Association. All rights reserved. CPT codes and CPT descriptions are from the current manuals and those included herein are not intended to be all-inclusive and are included for informational purposes only. Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

| CPT® Codes | Description | | |
|---------------|---|--|--|
| 11200 | Removal of skin tags, multiple fibrocutaneous tags, any area; up to and including 15 lesions | | |
| 11440 | Excision, other benign lesion including margins, except skin tag (unless listed elsewhere), face, ears, eyelids, nose, lips, mucous membrane; excised diameter 0.5 cm or less | | |
| 11441 | Excision, other benign lesion including margins, except skin tag (unless listed elsewhere), face, ears, eyelids, nose, lips, mucous membrane; excised diameter 0.6 to 1.0 cm | | |
| 11442 | Excision, other benign lesion including margins, except skin tag (unless listed elsewhere), face, ears, eyelids, nose, lips, mucous membrane; excised diameter 1.1 to 2.0 cm | | |
| 11443 | Excision, other benign lesion including margins, except skin tag (unless listed elsewhere), face, ears, eyelids, nose, lips, mucous membrane; excised diameter 2.1 to 3.0 cm | | |
| 11444 | Excision, other benign lesion including margins, except skin tag (unless listed elsewhere), face, ears, eyelids, nose, lips, mucous membrane; excised diameter 3.1 to 4.0 cm | | |
| 11446 | Excision, other benign lesion including margins, except skin tag (unless listed elsewhere), face, ears, eyelids, nose, lips, mucous membrane; excised diameter over 4.0 cm | | |
| 11640 | Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 0.5cm or less | | |
| 11641 | Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 0.6 to 1.0 cm | | |
| 11642 | Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 1.1 to 2.0 cm | | |
| 11643 | Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 2.1 to 3.0 cm | | |





| CPT® | Description | |
|-------------|---|--|
| Codes | 2 tstr.prion | |
| 11644 | Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter 3.1 to 4.0 cm | |
| 11646 | Excision, malignant lesion including margins, face, ears, eyelids, nose, lips; excised diameter over 4.0 cm | |
| 12051 | Repair, intermediate, wounds of face, ears, eyelids, nose, lips and/or mucous membranes; 2.5 cm or less | |
| 67800 | Excision of chalazion, single | |
| 67801 | Excision of chalazion, multiple, same lid | |
| 67805 | Excision of chalazion, multiple, different lids | |
| 67808 | Excision of chalazion; under general anesthesia and/or requiring hospitalization, single or multiple | |
| 67938 | Removal of embedded foreign body, eyelid | |
| 67961 | Excision and repair of eyelid, involving lid margin, tarsus, conjunctiva, canthus, or full thickness, may include preparation for skin graft or pedicle flap with adjacent tissue transfer or rearrangement; up to one-fourth of lid margin | |
| 67966 | Excision and repair of eyelid, involving lid margin, tarsus, conjunctiva, canthus, or full thickness, may include preparation for skin graft or pedicle flap with adjacent tissue transfer or rearrangement; over one-fourth of lid margin | |
| 67971 | Reconstruction of eyelid, full thickness by transfer of tarsoconjunctival flap from opposing eyelid; up to two-thirds of eyelid, 1 stage or first stage | |
| 67973 | Reconstruction of eyelid, full thickness by transfer of tarsoconjunctival flap from opposing eyelid; total eyelid, lower, 1 stage or first stage | |
| 67974 | Reconstruction of eyelid, full thickness by transfer of tarsoconjunctival flap from opposing eyelid; total eyelid, upper, 1 stage or first stage | |
| 67975 | Reconstruction of eyelid, full thickness by transfer of tarsoconjunctival flap from opposing eyelid; second stage | |
| 68110 | Excision of lesion, conjunctiva; up to 1 cm | |
| 68115 | Excision of lesion, conjunctiva; over 1 cm | |
| 68130 | Excision of lesion, conjunctiva; with adjacent sclera | |

ICD-10-CM Diagnosis Codes that Support Coverage Criteria

+ Indicates a code requiring an additional character

| ICD-10-CM | Description |
|-----------|---|
| Code | |
| C43.111 | Malignant melanoma of right upper eyelid, including canthus |
| C43.112 | Malignant melanoma of right lower eyelid, including canthus |
| C43.121 | Malignant melanoma of left upper eyelid, including canthus |
| C43.122 | Malignant melanoma of left lower eyelid, including canthus |
| C44.1021 | Unspecified malignant neoplasm of skin of right upper eyelid, including canthus |
| C44.1022 | Unspecified malignant neoplasm of skin of right lower eyelid, including canthus |
| C44.1091 | Unspecified malignant neoplasm of skin of left upper eyelid, including canthus |





| ICD-10-CM | Description | |
|-----------|---|--|
| Code | | |
| C44.1092 | Unspecified malignant neoplasm of skin of left lower eyelid, including canthus | |
| C44.1121 | Basal cell carcinoma of skin of right upper eyelid, including canthus | |
| C44.1122 | Basal cell carcinoma of skin of right lower eyelid, including canthus | |
| C44.1191 | Basal cell carcinoma of skin of left upper eyelid, including canthus | |
| C44.1192 | Basal cell carcinoma of skin of left lower eyelid, including canthus | |
| C44.1221 | Squamous cell carcinoma of skin of right upper eyelid, including canthus | |
| C44.1222 | Squamous cell carcinoma of skin of right lower eyelid, including canthus | |
| C44.1291 | Squamous cell carcinoma of skin of left upper eyelid, including canthus | |
| C44.1292 | Squamous cell carcinoma of skin of left lower eyelid, including canthus | |
| C44.131 | Sebaceous cell carcinoma of skin of unspecified eyelid, including canthus | |
| C44.1321 | Sebaceous cell carcinoma of skin of right upper eyelid, including canthus | |
| C44.1322 | Sebaceous cell carcinoma of skin of right lower eyelid, including canthus | |
| C44.1391 | Sebaceous cell carcinoma of skin of left upper eyelid, including canthus | |
| C44.1392 | Sebaceous cell carcinoma of skin of left lower eyelid, including canthus | |
| C44.1921 | Other specified malignant neoplasm of skin of right upper eyelid, including canthus | |
| C4A.111 | Merkel cell carcinoma of right upper eyelid, including canthus | |
| C4A.112 | Merkel cell carcinoma of right lower eyelid, including canthus | |
| C4A.121 | Merkel cell carcinoma of left upper eyelid, including canthus | |
| C4A.122 | Merkel cell carcinoma of left lower eyelid, including canthus | |
| C47.0 | Malignant neoplasm of peripheral nerves of head, face and neck | |
| C49.0 | Malignant neoplasm of connective and soft tissue of head, face and neck | |
| D03.111 | Melanoma in situ of right upper eyelid, including canthus | |
| D03.112 | Melanoma in situ of right lower eyelid, including canthus | |
| D03.121 | Melanoma in situ of left upper eyelid, including canthus | |
| D03.122 | Melanoma in situ of left lower eyelid, including canthus | |
| D04.111 | Carcinoma in situ of skin of right upper eyelid, including canthus | |
| D04.112 | Carcinoma in situ of skin of right lower eyelid, including canthus | |
| D04.121 | Carcinoma in situ of skin of left upper eyelid, including canthus | |
| D04.122 | Carcinoma in situ of skin of left lower eyelid, including canthus | |
| D22.111 | Melanocytic nevi of right upper eyelid, including canthus | |
| D22.112 | Melanocytic nevi of right lower eyelid, including canthus | |
| D22.121 | Melanocytic nevi of left upper eyelid, including canthus | |
| D22.122 | Melanocytic nevi of left lower eyelid, including canthus | |
| D23.111 | Other benign neoplasm of skin of right upper eyelid, including canthus | |
| D23.112 | Other benign neoplasm of skin of right lower eyelid, including canthus | |
| D23.121 | Other benign neoplasm of skin of left upper eyelid, including canthus | |
| D23.122 | Other benign neoplasm of skin of left lower eyelid, including canthus | |
| H00.011 | Hordeolum externum right upper eyelid | |
| H00.012 | Hordeolum externum right lower eyelid | |
| H00.014 | Hordeolum externum left upper eyelid | |





| ICD-10-CM | Description | | |
|-----------|---|--|--|
| Code | | | |
| H00.015 | Hordeolum externum left lower eyelid | | |
| H00.021 | Hordeolum internum right upper eyelid | | |
| H00.022 | Hordeolum internum right lower eyelid | | |
| H00.024 | Hordeolum internum left upper eyelid | | |
| H00.025 | Hordeolum internum left lower eyelid | | |
| H00.031 | Abscess of right upper eyelid | | |
| H00.032 | Abscess of right lower eyelid | | |
| H00.034 | Abscess of left upper eyelid | | |
| H00.035 | Abscess of left lower eyelid | | |
| H00.11 | Chalazion right upper eyelid | | |
| H00.12 | Chalazion right lower eyelid | | |
| H00.14 | Chalazion left upper eyelid | | |
| H00.15 | Chalazion left lower eyelid | | |
| H02.811 | Retained foreign body in right upper eyelid | | |
| H02.812 | Retained foreign body in right lower eyelid | | |
| H02.814 | Retained foreign body in left upper eyelid | | |
| H02.815 | Retained foreign body in left lower eyelid | | |
| H02.821 | Cysts of right upper eyelid | | |
| H02.822 | Cysts of right lower eyelid | | |
| H02.824 | Cysts of left upper eyelid | | |
| H02.825 | Cysts of left lower eyelid | | |
| S01.121A | Laceration with foreign body of right eyelid and periocular area initial encounter | | |
| S01.121D | Laceration with foreign body of right eyelid and periocular area subsequent encounter | | |
| S01.121S | Laceration with foreign body of right eyelid and periocular area sequela | | |
| S01.122A | Laceration with foreign body of left eyelid and periocular area initial encounter | | |
| S01.122D | Laceration with foreign body of left eyelid and periocular area subsequent encounter | | |
| S01.122S | Laceration with foreign body of left eyelid and periocular area sequela | | |
| S01.141A | Puncture wound with foreign body of right eyelid and periocular area initial encounter | | |
| S01.141D | Puncture wound with foreign body of right eyelid and periocular area subsequent encounter | | |
| S01.141S | Puncture wound with foreign body of right eyelid and periocular area sequela | | |
| S01.142A | Puncture wound with foreign body of left eyelid and periocular area initial encounter | | |
| S01.142D | Puncture wound with foreign body of left eyelid and periocular area subsequent encounter | | |
| S01.142S | Puncture wound with foreign body of left eyelid and periocular area sequela | | |





| Reviews, Revisions, and Approvals | | Approval |
|---|---------|----------|
| | | Date |
| Annual Review | | 12/2019 |
| Converted to new template | | 10/2020 |
| Annual Review | 12/2020 | 12/2020 |
| Annual Review; Updated ICD-10 diagnosis codes to include chalazia | | 01/2022 |
| and hordeola | | |
| Annual Review | | 12/2022 |
| Annual Review | | 12/2023 |
| Annual Review | | 12/2024 |
| Annual Review | | 10/2025 |

References

- 1. Kersten RC, Ewing-Chow D, Kulwin DR, Gallon M. Accuracy of clinical diagnosis of cutaneous eyelid lesions. Ophthalmology 1997;104:479-84.
- 2. James Kasenchak, MD, Gregory Notz, DO. Eyelid Lesions: Diagnosis and Treatment. Review of Ophthalmology. 5 April 2016.
- 3. Shields JA, Shields CL. Eyelid, Conjunctival, and Orbital Tumors. An Atlas and Textbook. LWW; Third edition October 9, 2015
- 4. Sara Weidmayer, OD, Molly McGinty-Tauren, OD. A Close Look at Common Lid Lesions. Review of Optometry. 15 November 2019.
- 5. Susan R. Carter, M.D. Eyelid Disorders: Diagnosis and Management. Am Fam Physician. 1998 Jun 1;57(11):2695-2702.
- 6. Sun, Michelle, MBBS, PhD, Huang, Sonia, Huilgol, Shyamala, MBBS, FACD, Selva, Dinesh DHSc FRANZCO. Eyelid lesions in general practice. Australian J of General Practice. Volume 48, Issue 8, August 2019.

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. "Health Plan" means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan's affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.





This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

Note: For Medicaid members, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

Note: For Medicare members, to ensure consistency with the Medicare National Coverage Determinations (NCD) and Local Coverage Determinations (LCD), all applicable NCDs, LCDs, and Medicare Coverage Articles should be reviewed <u>prior to</u> applying the criteria set forth in this clinical policy. Refer to the CMS website at https://www.cms.gov for additional information.

©2025 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.

©2025 Envolve, Inc. All rights reserved. All materials are exclusively owned by Envolve and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Envolve. You may not alter or remove any trademark, copyright or other notice contained herein.